Premium
Anti‐human neutrophil antigen‐1a, ‐1b, and ‐2 antibodies in neonates and children with immune neutropenias analyzed by extracted granulocyte antigen immunofluorescence assay
Author(s) -
Onodera Rie,
Kurita Emi,
Taniguchi Kikuyo,
Karakawa Shuhei,
Okada Satoshi,
Kihara Hirotaka,
Fujii Teruhisa,
Kobayashi Masao
Publication year - 2017
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1111/trf.14291
Subject(s) - antibody , antigen , immunofluorescence , granulocyte , neutropenia , immunology , monoclonal antibody , medicine , biology , chemotherapy
BACKGROUND Anti‐human neutrophil antigen (HNA) antibodies have been implicated in the development of neonatal alloimmune neutropenia (NAN) and autoimmune neutropenia (AIN). There are many conventional assay methods that detect anti‐HNA antibodies. However, a method to measure multiple samples and detect several anti‐HNA antibodies simultaneously is needed. STUDY DESIGN AND METHODS We developed a new method, the extracted granulocyte antigen immunofluorescence assay (EGIFA), to analyze anti‐HNA‐1a, ‐1b, and ‐2 antibodies in sera. The results obtained by EGIFA were evaluated in comparison with those from several standard assay methods. Anti‐HNA antibodies in serum samples from nine familial cases with suspected NAN (n = 19) and children with suspected AIN (n = 88) were also measured by EGIFA. RESULTS The evaluation of nine serum samples with anti‐HNA antibodies suggested that EGIFA demonstrated equivalent specificity and superior sensitivity to monoclonal antibody–specific immobilization of granulocyte antigens and had comparable sensitivity to the granulocyte indirect immunofluorescence test. EGIFA successfully detected anti‐HNA‐1a or ‐1b antibodies in seven of nine familial cases with suspected NAN. EGIFA detected anti‐HNA antibodies in 40.9% of children with suspected AIN. Among them, isolated anti‐HNA‐1a or ‐1b antibody was detected in 4.5 or 12.5% of children, respectively, and anti‐HNA‐2 antibody was identified in 3.4% of children. The 30.8% (16 of 52) of children negative for anti‐HNA antibody by EGIFA were positive for anti‐HLA antibody. CONCLUSION EGIFA facilitated the measurement of anti‐HNA‐1a, ‐1b, and/or ‐2 antibodies in sera. The prompt measurement of anti‐HNA antibodies will improve the diagnosis and clinical management of patients with suspected NAN or AIN.